Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

      10x Genomics Logo

      News provided by

      10x Genomics, Inc.

      Nov 16, 2026, 16:05 ET

      Share this article

      Share this article


      Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform

      PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, and the German Rheumatology Research Center Berlin (DRFZ). The second is with the Genomic Medicine Institute at Seoul National University (SNU), one of South Korea's leading research universities.

      Earlier this year, 10x outlined its clinical strategy for realizing the potential of single cell and spatial technologies in diagnostics, with a focus on oncology and autoimmune disease. These two new collaborations expand 10x's autoimmune disease research to Europe and Asia. Both collaborations plan to use Flex Apex to analyze longitudinal blood samples at single cell resolution. By pairing these profiles with clinical data, researchers aim to identify biomarkers of disease activity and treatment response.

      "Clinical decision-making in autoimmune disease depends on symptoms and tests that provide only indirect measures of underlying immune activity, while treatment selection relies on trial and error," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "By studying longitudinal cohorts across diseases, therapies and geographies, these collaborations can help identify robust, reproducible biomarkers of disease activity and treatment response. That evidence could lay the foundation for a new generation of blood-based diagnostics built on single cell measurements of immune activity, moving us closer to precision medicine for patients with autoimmune disease."

      Charité and DRFZ: Disease Activity and Treatment Response in Rheumatoid Arthritis, Lupus and Psoriatic Arthritis

      10x, Charité and DRFZ plan to conduct a multi-year study involving 750 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA). Patients will be followed longitudinally as they begin or adjust biologic or targeted therapies, with blood collected during routine clinical visits.

      Using Flex Apex, researchers intend to profile immune cells in the blood and connect changes in cellular states and biological pathways with clinical measures of disease activity. The study aims to identify and validate biomarkers that distinguish active from controlled disease and responders from non-responders to standard-of-care therapies

      "Patients with the same rheumatic disease can follow very different courses and respond differently to the same therapy," said Gerhard Krönke, Director of the Department of Rheumatology and Clinical Immunology at Charité. "Following patients over time will allow us to connect shifts in immune biology with clinical outcomes, which is essential to improving care."

      "Single cell profiling across a cohort of this size allows us to examine immune activity at a depth not captured by conventional inflammatory markers," said Eicke Latz, Scientific Director of the German Rheumatology Research Center (DRFZ). "Our goal is to identify robust biomarkers that are consistent across diseases, therapies and patient populations."

      Seoul National University: Predicting Response to JAK Inhibitors in Alopecia Areata

      The study with SNU will focus on alopecia areata, an autoimmune disease that can cause hair loss. The collaboration brings together the Genomic Medicine Institute (GMI) and researchers from SCAID, building on patient cohorts and biospecimens established through the SCAID research program. Researchers plan to use Flex Apex to analyze longitudinal blood samples from patients with moderate-to-severe alopecia areata who received treatment with a JAK inhibitor therapy.

      By comparing immune profiles before and during treatment with clinical outcomes, the collaboration aims to identify baseline biomarkers that may predict treatment response and early molecular changes that may indicate whether a patient is responding. Researchers will also examine biological differences among patients who respond quickly, respond more slowly or do not respond to treatment.

      "Patients with alopecia areata can respond differently to JAK inhibitor therapy. By linking longitudinal single-cell immune profiles with clinical outcomes, we aim to understand the biology underlying these differences and identify candidate biomarkers of treatment response. We hope this work will provide a foundation for more informed treatment decisions in the future," said Professor Jong-Il Kim, Head of the Genomic Medicine Institute (GMI) of Seoul National University.

      Both collaborations will explore how findings could be translated into future reporting frameworks for disease monitoring and treatment planning.

      About 10x Genomics
      10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

      About Charité – Universitätsmedizin Berlin
      With more than 100 departments and institutes spanning four campuses, Charité – Universitätsmedizin Berlin is one of Europe's largest university medical centers. As a cutting-edge medical institution, Charité is a leader in the diagnosis and treatment of severe, complex and rare diseases. Combining first-class patient care with excellence in research and innovation, state-of-the-art teaching, and high-quality training and education, Charité has earned an outstanding reputation worldwide as both a medical school and a university medical centre.

      About the German Rheumatology Research Center Berlin
      The DRFZ is a Leibniz Institute dedicated to improving the understanding, diagnosis, treatment, and care of people with immune‑mediated rheumatic diseases. The institute combines basic research, systems biology, translational research, and epidemiology with state‑of‑the‑art technologies to develop preventive approaches and personalised—potentially curative—treatments. Using nationwide data and large patient cohorts, the DRFZ assesses disease burden, identifies risk factors, uncovers gaps in health care, and evaluates how well therapies work in real life. These insights guide the research and help ensure that new discoveries lead to meaningful improvements in patients' lives.

      About the Genomic Medicine Institute at Seoul National University
      The Genomic Medicine Institute (GMI) is part of the Medical Research Center at Seoul National University. This collaboration involves researchers from SCAID, a research program initiated in 2022 to build single-cell maps of immune-mediated diseases using patient blood and tissue samples.

      Contacts
      Investors: [email protected]
      Media: [email protected]

      SOURCE 10x Genomics, Inc.

      Modal title

      Also from this source

      Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

      Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

      10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that ...

      10x Genomics Reports Third Quarter 2026 Financial Results

      10x Genomics Reports Third Quarter 2026 Financial Results

      10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Education

      Education

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.